Download Free Sample Report

Hypocalcaemia Treatment Market, Global Outlook and Forecast 2022-2028

Hypocalcaemia Treatment Market, Global Outlook and Forecast 2022-2028

  • Published on : 12 July 2022
  • Pages :62
  • Report Code:SMR-7202783

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Hypocalcaemia is imbalance of electrolytes which is indicated by abnormally low level of calcium in the body. A healthy person has 8.5-10.2 mg/dL calcium level in his/her body, however, drop in this level could possibly led to hypocalcaemia disorder. Middle aged population needs to take 1000 mg of calcium while geriatrics population aged 65 and above should take 1500 mg of calcium per day. Hypocalcaemia is caused by hypoalbuminemia, hyperphosphatemia, surgical effects, medication effects, hypomagnesemia, heart failure, muscle cramps, vitamin D deficiency, alcoholism, magnesium deficiency, insufficient protein in the blood, in the blood and many more. Neuromuscular irritability is the most common sign of hypocalcaemia. Hypocalcaemia are mostly diagnosed by clinical suspicion and laboratory testing. Hypoparathyroidism has a major effect on hypocalcaemia and high recurrence rate.
This report contains market size and forecasts of Hypocalcaemia Treatment in Global, including the following market information:
Global Hypocalcaemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hypocalcaemia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Asymptomatic Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hypocalcaemia Treatment include F. Hoffman La Roche, Novo Nordisk, Sanofi, GlaxoSmithKline (GSK), Pfizer Inc. and Ranbaxy Pharmaceuticals Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hypocalcaemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypocalcaemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hypocalcaemia Treatment Market Segment Percentages, by Type, 2021 (%)
Asymptomatic
Symptomatic
Prophylactic
Global Hypocalcaemia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hypocalcaemia Treatment Market Segment Percentages, by Application, 2021 (%)
Hosptial
Clinic
Global Hypocalcaemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hypocalcaemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypocalcaemia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hypocalcaemia Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffman La Roche
Novo Nordisk
Sanofi
GlaxoSmithKline (GSK)
Pfizer Inc.
Ranbaxy Pharmaceuticals Ltd.